(Q49055513)

English

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

scientific article published in May 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

0 references

rhinoconjunctivitis

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

author name string

Bachert C

1

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Vestenbaek U

2

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Christensen J

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Griffiths UK

4

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Poulsen PB

5

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

publication date

1 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Clinical & Experimental Allergy

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

37

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

5

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

772-779

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

The impact of allergic rhinitis on bronchial asthma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

A comparative review of generic quality-of-life instruments

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

EuroQol: the current state of play

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

The use of quality-adjusted life-years in cost-effectiveness studies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2222.2007.02706.X

21 January 2018

Identifiers

10.1111/J.1365-2222.2007.02706.X

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/17456225

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49055513&oldid=1250904173"